Literature DB >> 9834815

The fine points of end points: phase II trials in lung cancer.

K A Gelmon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9834815     DOI： 10.1023/a:1008429313403

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer.

Authors:  Kensuke Kataoka; Ryujiro Suzuki; Hiroyuki Taniguchi; Yasunobu Noda; Joe Shindoh; Syuichi Matsumoto; Yoshiaki Watanabe; Kousuke Honda; Kiyoshi Suzuki; Kenji Baba; Kazuyoshi Imaizumi; Hiroaki Kume; Yoshinori Hasegawa; Kenzo Takagi
Journal:  Lung       Date:  2006 May-Jun       Impact factor: 2.584

2.  Cancer imaging - the significance of the findings.

Authors:  R H Reznek
Journal:  Cancer Imaging       Date:  2000-10-09       Impact factor: 3.909
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.